Abdulrahman Al-Mashdali։ Immune Checkpoint Inhibitor Associated HLH
Abdulrahman Al-Mashdali, Hematology Chief Fellow at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Clinical Medicine Insights: Oncology, adding:
”Excited to share our latest work on immune checkpoint inhibitor–associated hemophagocytic lymphohistiocytosis (ICI-HLH) — a rare but potentially fatal immune-related toxicity that is increasingly recognized in clinical practice.
In this systematic review, we analyzed 96 patients from 78 published reports, providing one of the most comprehensive patient-level summaries of ICI-associated HLH to date.
A few key findings:
- HLH developed early, after a median of 2 ICI cycles and 30 days from treatment initiation.
- Fever (97.9 percent) and cytopenias (97.8 percent) were the dominant clinical features, with marked hyperferritinemia.
- Diagnostic approaches were highly heterogeneous, including HLH-2004 criteria, HScore, combined criteria, and clinician-based
diagnosis. - Although 83 percent of patients improved or achieved resolution, mortality remained substantial at 25.3 percent.
- ICI rechallenge was rarely reported and was associated with recurrent HLH in 3 of 7 patients.
Our findings emphasize the importance of maintaining a high index of suspicion for HLH in patients receiving ICIs who develop persistent fever, cytopenias, and markedly elevated ferritin, as well as the need for earlier multidisciplinary assessment and more standardized diagnostic and treatment strategies.
I am very grateful to all my coauthors and collaborators for their valuable contributions Fatihelmgib Mohamed Mujahid Osama Abdelraof Shehab Mohamed Mohammed Elmourtada Abdulgayoom, thoughtful discussions, and continued support throughout this project.”
Title: Immune Checkpoint Inhibitor–Associated Hemophagocytic Lymphohistiocytosis: A Systematic Review
Authors: Abdulrahman F. Al-Mashdali, Fatihelmgib Mohamed, Marwa Osman, Mujahid O. Abdelraof, Mohammed Abdulgayoom, Shehab F. Mohamed
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 10, 2026, 09:05Wolfgang Miesbach: Moving from Bleed Control to Comprehensive Joint Health
-
Oct 10, 2026, 07:59Leila Caroline Souza Reis: Enoxaparin Dosing for VTE Prevention in Adults With Obesity
-
Oct 10, 2026, 07:41Adeeb Bazuhair: New Evidence for Catheter Directed Thrombolysis in Acute PE
-
Oct 10, 2026, 07:22Poppy Clarke: Turning Steps Into Support for Thrombosis Awareness
-
Oct 10, 2026, 07:12Hamzah Khan: The Role of Genuine Curiosity in Driving High-Impact Academic Research
-
Oct 10, 2026, 06:58Nita Radhakrishnan: Turning Evidence Into Action for Hemophilia Care in India
-
Oct 10, 2026, 06:48Nutan Kaushik: HemeNext 2.0 Brings Global Perspectives to Hematology
-
Oct 10, 2026, 06:43Suthesh Sivapalaratnam: Advancing Bleeding Disorder Care at EHC 2026
-
Oct 10, 2026, 02:38Brianne D.: Sex Differences in RIPK1 Signaling Following Intracerebral Hemorrhage